FDA Approves DOXYCYCLINE — Cranbury Pharmaceuticals, LLC

Cranbury Pharmaceuticals, LLC received FDA approval on October 7, 2019, for Doxycycline Hyclate oral tablets, expected to increase generic supply and exert downward pressure on the brand market. This ANDA approval allows the company to enter a wide-ranging therapeutic market currently dominated by branded competitors like Micro Labs.